

**EFFECTS OF DIACUTUANEUS FIBROLYSIS ON
MECHANOSENSITIVITY, DISABILITY AND NERVE
CONDUCTION STUDIES IN MILD TO MODERATE CARPAL
TUNNEL SYNDROME. SECONDARY ANALYSIS OF A
RANDOMIZED CONTROLLED TRIAL.**

Journal:	<i>Physical Therapy</i>
Manuscript ID	PTJ-2019-0666.R1
Manuscript Category:	Original Research Report - Other
Section:	Musculoskeletal
Keywords:	Carpal Tunnel Syndrome, Musculoskeletal Manipulations, Physical Therapy Modalities

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

EFFECTS OF DIACUTUANEUS FIBROLYSIS ON MECHANOSENSITIVITY, DISABILITY AND NERVE CONDUCTION STUDIES IN MILD TO MODERATE CARPAL TUNNEL SYNDROME. SECONDARY ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL.

ABSTRACT

Background. Patients diagnosed with Carpal Tunnel Syndrome (CTS) present fibrosis between the soft, connective, and neural tissues that could influence the compressive situation of the median nerve. The Diacutaneous Fibrolysis (DF) technique may release tissue adhesions and increase the mobility of connective tissues.

Objective. The purpose of this study was to compare the outcomes of DF in patients with mild to moderate CTS, on: mechanosensitivity, disability, and nerve conduction studies.

Design. This was a secondary analysis of a double-blinded, randomized placebo-controlled trial.

Settings. Patients were recruited between April to September 2016 from the Department of Neurophysiology at the Hospital ██████████ Zaragoza, Spain.

Participants. Thirty-nine people (52 wrists) diagnosed with mild to moderate CTS were included.

Intervention. Participants were randomly assigned to the DF group (n=26) or the Sham group (n=26). Both groups received 5 therapy sessions, two per week.

Measurements. Mechanosensitivity with Upper Limb Neurodynamic Test 1 (ULNT1), symptoms severity and functional status with Boston Carpal Tunnel Questionnaire (BCTQ), and median nerve sensory conduction velocity with nerve conduction studies were the outcomes measured. Assessments were undertaken at baseline and after the intervention.

Results. DF group showed significant improvements between-group on mechanosensitivity, 28.46° elbow extension ROM (95% CI = 19.2-37.7); on the mean difference for BCTQ symptoms severity and functional status score, 1.0 points (95% Confidence interval (CI) = 0.7-1.4); and for sensory conduction velocity of median nerve, 5.8 m/s (95% CI = 2.5-9.2).

Limitations. Patients with severe CTS were not included, and no long-term effects were assessed.

Conclusion. Patients with mild to moderate CTS experience benefit with five sessions of DF on symptoms severity, functional status, mechanosensitivity, and nerve conduction studies.

Key Words: Carpal Tunnel Syndrome; Physical Therapy Modalities; Outcomes.

WORD COUNT:

Number of words Abstract: 272

Number of words text: 3152

Number of tables: 3

Number of figures: 4

Number of references: 63

46 INTRODUCTION

47 Carpal Tunnel Syndrome (CTS) is the most common entrapment neuropathy of the
48 human body,^{1,2} with an estimated prevalence between 6.3% and 11.7%.^{3,4}

49 **The impairment of the median nerve in the CTS could be secondary to mechanical**
50 **compression and local ischemia.**⁵ Clinically, patients with CTS suffer paresthesia and
51 numbness symptoms, in the first three fingers and upper limb disability.

52 Besides the compressive signs, patients with CTS also present biomechanical changes in
53 the transverse carpal ligament (TCL), and degenerative changes in the neural connective
54 tissue and adjacent tenosynovium.⁶⁻⁸ Also, there is increasing evidence that has shown
55 fibrosis in the wrist and forearm soft tissues nearby the median nerve.⁹⁻¹³

56 The fibrosis between the soft, connective, and neural tissues could influence the
57 compressive situation of the median nerve. **This compression generates an edematic**
58 **condition, which results in a nerve conduction velocity alteration. In addition, these**
59 **impairments could decrease nerve mobility and increase mechanosensitivity.**^{11,12,14}
60 **Upper Limb Neurodynamic Test 1 (ULNT1) is used to assess the mechanosensitivity**
61 **of the median nerve, according to the movements performed and the range of motion**
62 **(ROM) achieved.**^{15,16}

63 Recently, several authors have proposed soft tissue mobilization to decrease the
64 compressive situation, improving clinical signs and symptoms in patients with CTS.¹⁷⁻¹⁹

65 Diacutaneous Fibrolysis (DF) is a **physiotherapeutic technique, developed from**
66 **Cyriax deep friction massage principles, that uses a set of metallic hooks to achieve**
67 **a deeper and more precise application than the manual treatment. DF** is a novel
68 technique that mechanically tries to release tissue adhesions and increase the mobility of
69 connective tissues. This technique has shown an improvement in the mobility of other
70 human body structures in musculoskeletal disorders, such as shoulder **pain,**^{20,21} **lateral**

epicondylalgia,²² and triceps surae tendon muscle reflexes.^{23,24} In this sense, the improvement of the mobility between tissues with the DF technique could alleviate the mechanical compression of the median nerve in the carpal tunnel. **The reduction of the epineurial tethering in the forearm could improve the median nerve gliding in the carpal tunnel during the movement of the wrist, fingers or elbow.**

We hypothesize that the application of DF in patients with mild to moderate STC will reduce severity symptoms and increase functional status, reduce mechanosensitivity and improve nerve conduction velocity, by restoring the connective, muscle, and tendon tissue movement.

Therefore, this secondary analysis hypothesized that the effect of DF compared with Sham fibrolysis, would be greater on symptom severity and functional status, mechanosensitivity, and nerve conduction test, in patients with mild to moderate CTS.

METHODS

Trial design

This study was a secondary analysis of data from a double-blind, randomized, placebo-controlled trial¹⁹ (ClinicalTrials.gov Identifier: C.I.PI14/00086), and was approved by the Ethics Committee of Aragón, Spain (CP13/2014). All patients provided written informed consent before enrollment in the study. The analysis in the present study was not included in the original protocol for the randomized controlled trial. **Cases included in this secondary analysis were those who completed the entire ULNT1 until the elbow extension phase from the sample analyzed in the primary study.** The study was carried out according to CONSORT guidelines.²⁵

Participants and Setting

The trial was carried out in the Department of Neurophysiology at the Hospital [REDACTED], Zaragoza, Spain. Participant recruitment period was between April to September 2016. The participants were volunteers diagnosed with mild to moderate CTS by a neurophysiologist.

The inclusion criteria were as follows: aged 18 to 65 years, symptoms (**numbness, tingling, burning, or pain**) in the median nerve distribution, diagnosed with mild to moderate CTS, according to the American Academy of Physical Medicine and Rehabilitation criteria,²⁶ completed the entire ULNT1 until elbow extension phase, capable of providing information to complete questionnaires and understand the instructions, and complete all treatment sessions.

The exclusion criteria were as follows: previous surgery in the affected upper extremity or cervical spine, a specific cause of CTS (i.e. trauma, infectious process, cervical radiculopathy, alcoholism, vitamin deficiency, systemic diseases), pregnancy, previous physiotherapy treatment or corticosteroid injections in the upper limb in the last 3 months, and contraindications for the DF treatment (anticoagulant therapy or vascular alterations, wounds or skin disorders) in the elbow, forearm or hand region.

Outcomes

Two examiners blinded to the patients' allocation performed the measurements. The therapist could not be blinded to the group assignment, but he was not involved in any of the outcome measures. **The outcomes were measured at baseline and after treatment.** **The primary outcome variable was symptoms severity and functional status.** The secondary outcome variables were mechanosensitivity and nerve conduction studies of the median nerve at the carpal tunnel.

The symptoms severity and functional status were assessed using the Spanish version of the Boston Carpal Tunnel Questionnaire (BCTQ).²⁷ BCTQ has shown to be valid and reliable in patients with CTS.²⁷ This questionnaire has shown an excellent reliability with an intraclass correlation coefficient (ICC [2,k]) ranged from 0.91 to 0.94. The 95% confidence interval (95%CI) ranged between 0.84 to 0.99 and the minimal detectable change at the 95% confidence level (MDC₉₅) has been stated in 0.74 in patients with CTS.²⁸

Mechanosensitivity was measured using the ULNT1. The ULNT1 consists of a sequence of passive movements to test the brachial plexus through the median nerve.^{29–32} In the present study, the ULNT1 was sequenced by examiner 1, as follows (**Figure 1**): 90° shoulder abduction, 90° shoulder external rotation with the shoulder girdle maintained in neutral, the forearm in maximum supination, the wrist and fingers maximally extended. Patients were instructed to communicate the first symptoms. Elbow extension was performed at the onset of symptoms.^{32–35} In that point, the examiner 2 performed the structural difference maneuver to classify the response.¹⁶ **Structural differentiation maneuver is defined as a movement of a distant body part that further loads or unloads the nervous system³². In the ULNT1, if the symptoms are in the distal part of the upper limb, the structural differentiation consists of performing contralateral neck side bending, without changing tension in the adjacent structures, such as muscles or tendons of the forearm and the hand area (Figure 1). If the symptoms are in the proximal part of the upper limb, the structural differentiation consists of performing wrist palmar flexion. When the symptoms change with the structural differentiation maneuver, the response is classified as a neurodynamic response.**

The ULNT1 was registered at the onset of symptoms, as the following variables:

- Elbow ROM, measured with a universal goniometer.³⁶ **The measurement of elbow extension ROM at pain onset during ULNT1 has shown an ICC(2,1)=0.85 with the 95%CI ranging from 0.84 to 0.99.^{36,37} The MDC₉₅ has been determined in 10.47°.^{36,37}**
- Type of symptoms, classified in stretching, pain, tingling, pricking, numbness, or burning sensation.³⁸
- Symptoms intensity, measured with a 10cm visual analogue scale (VAS), where 0 represented “no symptoms” and 10 “the most intense pain imaginable”.
- Location of the symptoms, registered in a body chart divided into 7 areas: forearm, wrist, three first fingers, hand, elbow, arm, and ulnar area.³⁸

The sensory conduction velocity (SCV) of the median nerve at the wrist was measured with nerve conduction studies,^{26,39} by a neurophysiologist, blinded to the patient’s assigned group.

Randomization and Interventions

The participants were randomly assigned to the DF group or the Sham group. The randomization sequence was computer-generated (research randomizer version 4.0) by an external clinical assistant before patient recruitment. Both the examiners and the patients were blinded to the assigned group. In bilateral cases, the same intervention was performed on both sides to maintain blinding.

DF and the Sham intervention were applied by the first author, blinded to the measurements, who had received training in DF and had 5 years’ clinical experience. All cases participated in 5 sessions of treatment (20 minutes each, 2-5 days between sessions).

In the DF group, the hook was applied with the necessary pressure for covering the

structure, to move and traction in the transverse direction. These procedures were performed with the hook fixed on the skin and underlying soft tissues. The position of the patient was in supine with the forearm on a stable support to allow access to the muscular tissue. With the forearm of the patient positioned in supination, the DF was applied as deeply as possible following the intermuscular septum between the ventral muscles of the forearm: pronator teres, flexor carpi radialis, palmaris longus, flexor carpi ulnaris, and finger flexors. The finger flexor tendons and palmar fascia were also treated. **The cases included presented symptoms in the distal part of the upper limb (wrist and hand), so the intervention was applied from the elbow and proximal forearm to wrist, hand, and fingers, according to the centripetal approach (Figure 2A).**

In the Sham group, the hook was applied over the same forearm and hand area and in the same direction, but only at a superficial level and without any mechanical action taking place on the deep tissue layers. **A pinch of skin was held with the thumb of the palpatory hand and the tip of the hook, so that, the patient could feel the hook distinctly (Figure 2B).**

Both interventions lasted 5 sessions (20 minutes each, 2-5 days between sessions). **No other treatment modality was added to the intervention.**

Sample size

Of the 60 cases analyzed in the primary study, 52 cases met the inclusion criteria for this secondary analysis. The secondary sample sizes were n=26 cases in the DF group (18 subjects) and n=26 cases in the Sham group (21 subjects), for a sample size of 52 cases with CTS.

Because of the sample size has not been estimated for this secondary study, the statistical power of the sample for the primary outcome has been calculated. The

observed statistical power demonstrated by the sample was 99.9%, with an α error of 5%, with a consequent β error (type II) of 0.1 %.

Data Analysis

SPSS 20.0 software was used for all statistical analyses. Frequencies and percentages were calculated for qualitative variables: the quality and the location of the patients' responses during ULTN1.

Mean and standard deviations were calculated for quantitative variables: elbow extension ROM and the intensity of the patients' responses during the ULTN1, and SCV of the median nerve at the wrist. The Shapiro-Wilk test was used to assess the normal distribution of quantitative data. Differences between groups at baseline were analyzed by Student's t-test or the Mann-Whitney U test, for normally distributed data or non-normally distributed data respectively. Chi-square test (χ^2 test) or Fisher's exact test was used for the demographic nominal variables. A two-way analysis of variance (ANOVA) was used to investigate the differences in outcomes with time (baseline and end of the treatment) as the within-subjects factor and group (FD, Sham) as the between-subjects factor. A p-value <0.05 was considered statistically significant.

The effect size was calculated with Cohen coefficients (d) and interpreted as follows: large effect sizes, $d>0.8$; moderate effect sizes, $d=0.5-0.79$; and small effect sizes, $d=0.2-0.49$.⁴⁰

RESULTS

Fifty-two cases met the inclusion criteria for this secondary analysis (39 subjects, 13 bilateral and 26 unilateral). The study flowchart is shown in Figure 3.

219 Baseline characteristics among the groups were similar for demographic characteristics
 220 (Table 1). Adverse events or side effects were not reported nor observed for any
 221 participant.

222 **The symptoms in ULNT1 appeared in the distal part of the upper limb and the**
 223 **responses obtained in all cases, at baseline and after treatment, were neurodynamic.**

224 At baseline, no significant differences between the DF and Sham groups for elbow
 225 extension ROM ($p=0.51$), the intensity of the sensations in ULTN1 ($p=0.06$), SCV of the
 226 median nerve at the wrist ($p=0.34$) and **BCTQ** score ($p=0.33$) were found.

227 Table 2 provides at baseline, post-intervention data, and effect sizes as well as within-
 228 group, and between-group differences for ROM in ULNT1, the intensity of the sensations
 229 in ULTN1, for SCV and **BCTQ** score. A two-way ANOVA revealed a significant Group
 230 by Time Interaction for the ULTN1 elbow extension ROM ($df =1$; $F=37.191$,
 231 $p<0.01$), and the intensity of symptoms during ULTN1 ($df =1$; $F=5.777$, $p=0.02$). A
 232 significant Group by Time interaction was also detected for SCV median nerve ($df =1$;
 233 $F=12.227$, $p<0.01$), and **BCTQ** symptoms severity and functional status score ($df =1$;
 234 $F=14.914$, $p<0.01$). Mechanosensitivity, symptoms severity and functional status, and the
 235 SCV median nerve improved in the DF group ($p>0.05$). The results achieved for all the
 236 variables in the DF group showed a large effect size ($d \geq 0.9$).

237 **At baseline, the main descriptors of the type of symptoms in ULNT1 were stretching**
 238 **(65.4% in the Sham group, 73.1% in the DF group) and pain (23.1% in the Sham group,**
 239 **19.2% in the DF group). The DF group increased the tightness sensation (80.8%) and**
 240 **decreased the pain sensation (15.4%) in ULTN1. However, in the Sham group decreased**
 241 **the stretching sensation (50.0%) and increased the pain sensation (38.5%) in ULTN1**
 242 **(Table 3).**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

243 **At baseline, in ULNT1, the location of symptoms (stretching, pain or tightness),**
244 **independently of the type of symptoms, had no differences between groups (Figure**
245 **4).** After the intervention, in the DF group, the symptoms provoked by the ULTN1
246 decreased in the wrist (30.8%), the elbow (3.8%) and increased in the forearm (53.8%)
247 and hand (7.7%). The Sham group did not show differences after treatment in the location
248 of symptoms in ULTN1 (Figure 4).

250 **DISCUSSION**

251 To our knowledge, this is the first study to evaluate the short terms effects of DF treatment
252 on symptoms severity and functional status, **mechanosensitivity**, and nerve conduction
253 studies in patients with mild to moderate CTS. The results demonstrated that DF treatment
254 compared with Sham DF significantly improved the severity of symptoms and functional
255 status, and mechanosensitivity in patients with mild to moderate CTS. Also, an
256 improvement in the nerve conduction studies was found in favor of the DF group. This
257 result **is in agreement with** a previous study.¹⁹

259 **Strengths and Weakness in Relation to Other Studies**

260 Based on our findings, DF had positive effects on hand symptoms and functional status.
261 The results obtained on **BCTQ** severity symptoms and functional status scores were
262 higher than the MDC.²⁸ The elbow extension ROM in ULNT1 increased after treatment
263 in the DF group, suggesting a decrease of mechanosensitivity.^{38,41} The improvement in
264 elbow extension ROM in ULNT1 was superior to the MDC reported for ULNT1 in
265 previous studies.^{36,37,42,43} Also, the effect size values were greater than 1, in favor of the
266 DF group, indicating a large effect.

Previous systematic reviews and clinical trials have studied different conservative non-invasive treatments, such as manual therapy, soft tissue mobilization, splinting, laser, ultrasounds, thermotherapy, or its combination.^{18,44-49} The studies that applied non-invasive treatments, focusing on carpal tunnel area, showed positive effects on the **BCTQ** score,^{44,45} however, they did not achieve positive effects on nerve conduction studies.⁴⁶⁻⁴⁸ The studies that applied the intervention in the soft tissues of the entire upper limb demonstrated positive clinical effects on **BCTQ** score and nerve conduction study.^{18,49,50} Thus, the treatment of the tissues of the specific structures related to the median nerve improved the symptoms severity and the nerve conduction studies. This is the first clinical trial that considers a deep instrumental intervention, focusing on the specific structures related to the median nerve. Additionally, it has achieved clinically relevant and statistically significant changes on **BCTQ**, nerve conduction studies and on mechanosensitivity, measured by ULNT1.

Concerning ULNT1, the mean value obtained in elbow extension ROM after DF treatment was minor than the mean ROM described as the normal response in asymptomatic subjects.⁵¹ This difference could be related to the point where the movement was stopped. In our study, the test was stopped when the patients felt the first onset of any symptoms, whereas in other studies the test was stopped at the point of maximal tolerance. Boyd et al.⁵² showed a mean difference higher than 20° of ROM between the point of the first report of symptoms and the point of maximal tolerance in neurodynamic tests.

Besides, in this study, other secondary variables of ULNT1, such as sensory responses, location, type, or intensity of symptoms, were measured. Also, these variables have been used for the CTS diagnosis.^{16,38,41,42,53,54} In the present study, all the sensory variables of the ULNT1 showed significant changes after DF treatment. Stretching in the forearm was

the main symptom in ULNT1 after DF treatment. This outcome was similar to the response described in asymptomatic subjects during ULNT1.^{38,51,53,55}

Explanation of Findings

The treatment of the structures surrounding the median nerve appears to be important in patients with mild to moderate CTS. Previous studies have reported that soft tissue mobilization techniques improved the CTS symptoms.^{56,57}

The positive results achieved in BCTQ and nerve conduction studies could be related to the soft tissue mobilization and the release of the adhesences.

It has been demonstrated that the median nerve glides directionally in the carpal tunnel during movement of the wrist, fingers or elbow, and that epineurial tethering in the forearm may reduce the nerve excursion in the tunnel, resulting in transverse contraction of the nerve and a resultant increase in intraneural pressure.^{56,57}

Improvements in mechanosensitivity detected with ULNT1 reflected that patients improved mechanical tolerance. The fact of having treated soft tissues related to neural compression could have indirectly generated an improvement in the function of the nervous system. This outcome could have generated better tolerance to the tension. This fact could explain the positive results achieved by other authors that treated soft tissues around the nerve.^{18,49,58}

Strengths and Limitations of the Trial

From a clinical perspective, the approach based on DF applied in the soft and connective tissue around the median nerve showed that the DF technique improves the severity of symptoms and functional status and **reduces the mechanosensitivity of the median nerve in patients with mild to moderate CTS.**

Changes in mechanosensitivity could be a relevant clinical sign in the assessment of the patients with minor peripheral nerve injuries.⁵⁹ In patients with mild to moderate CTS, **the neurodynamic test** could be an important tool, because nerve conduction studies are not always clear in minor nerve disorders.^{36,41,60–62}

The present study has some limitations. Firstly, it was not a preplanned secondary subgroup analysis, that may condition a type 1 error, neither was the elbow extension phase of ULNT1 used as a selection factor at randomization. This factor could have created unbalanced groups that could have influenced the outcomes. Another potential limitation is that the study did not include severe CTS, which limits the generalization of the results. Also, the lack of studies assessing mechanosensitivity has not allowed comparing with our results. **Also, the fact that a single therapist provisioned of all treatment, reduces the generalizability of the findings to treatments by other practitioners.** Finally, no long terms effects were assessed.

Future research should study the medium and long terms of DF treatment in patients with mild to moderate CTS, the effects of DF treatment in severe CTS and the combination of DF treatment with other techniques, which have reported clinical benefits in patients with CTS, such as neurodynamic mobilizations. Finally, it could be interesting to assess the appropriate dosage and the cost-effectiveness of DF treatment in CTS patients.

Declaration of conflicting interests:

The author(s) declared that there is no conflict of interest with respect to the research. Authorship, and/or publication of this article.

Funding

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

341 The author(s) declared that no received any financial support for the research, authorship
342 or publication.

343
344 **REFERENCES**

345 1. Keith MW, Masear V, Chung KC, et al. American Academy of Orthopaedic
346 Surgeons Clinical Practice Guideline onDiagnosis of Carpal Tunnel Syndrome. *J*
347 *Bone Jt Surg.* 2009;91(10):2478-2479. doi:10.2106/JBJS.I.00643
348 2. Ibrahim I, Khan WS, Goddard N, Smitham P. Carpal tunnel syndrome: a review
349 of the recent literature. *Open Orthop J.* 2012;6:69-76.
350 doi:10.2174/1874325001206010069; 10.2174/1874325001206010069
351 3. Dale AM, Harris-Adamson C, Rempel D, et al. Prevalence and incidence of
352 carpal tunnel syndrome in US working populations: pooled analysis of six
353 prospective studies. *Scand J Work Environ Health.* 2013;39(5):495.
354 doi:10.5271/sjweh.3351
355 4. Luckhaupt SE, Dahlhamer JM, Ward BW, Sweeney MH, Sestito JP, Calvert GM.
356 Prevalence and work-relatedness of carpal tunnel syndrome in the working
357 population, United States, 2010 national health interview survey. *Am J Ind Med.*
358 2013;56(6):615-624. doi:10.1002/ajim.22048
359 5. Werner R, Andary M. Carpal tunnel syndrome: pathophysiology and clinical
360 neurophysiology. *Clin Neurophysiol.* 2002;113(9):1373-1381.
361 doi:10.1016/S1388-2457(02)00169-4
362 6. Shen ZL, Li Z-M. Biomechanical interaction between the transverse carpal
363 ligament and the thenar muscles. *J Appl Physiol.* 2013;114(2):225-229.
364 doi:10.1152/japplphysiol.01273.2012
365 7. Schuind F, Ventura M, Pasteels J. Idiopathic carpal tunnel syndrome: histologic

- study of flexor tendon synovium. *J Hand Surg Am.* 1990;15(3):497-503.
doi:10.1016/0363-5023(90)90070-8
8. Allampallam K, Chakraborty J, Bose KK, Robinson J. Explant culture, immunofluorescence and electron-microscopic study of flexor retinaculum in carpal tunnel syndrome. *J Occup Environ Med.* 1996;38(3):264-271.
doi:10.1097/00043764-199603000-00011
9. Werthel JD, Zhao C, An KN, Amadio PC. Carpal tunnel syndrome pathophysiology: role of subsynovial connective tissue. *J Wrist Surg.* 2014;3(4):220-226. doi:10.1055/s-0034-1394133
10. Yesil M, Bacakaoglu AK, Dogan M. Are myofibroblasts activated in idiopathic carpal tunnel syndrome? an immunohistochemical study. *Jt Dis Relat Surg.* 2014;25(3):133-140. doi:10.5606/ehc.2014.29
11. Keir PJ, Bach JM. Flexor muscle incursion into the carpal tunnel: a mechanism for increased carpal tunnel pressure? *Clin Biomech (Bristol, Avon).* 2000;15(5):301-305. doi:S0268-0033(99)00092-3
12. Kociolek AM, Tat J, Keir PJ. Biomechanical risk factors and flexor tendon frictional work in the cadaveric carpal tunnel. *J Biomech.* 2015;48(3):449-455. doi:10.1016/j.jbiomech.2014.12.029
13. Yoshii Y, Zhao C, Zhao KD, Zobitz ME, An KN, Amadio PC. The effect of wrist position on the relative motion of tendon, nerve, and subsynovial connective tissue within the carpal tunnel in a human cadaver model. *J Orthop Res.* 2008;26(8):1153-1158. doi:10.1002/jor.20640
14. Keir PJ, Rempel DM. Pathomechanics of peripheral nerve loading. Evidence in carpal tunnel syndrome. *J Hand Ther.* 2005;18(2):259-269.
doi:S0894113005000414

- 391 15. Koulidis K, Veremis Y, Anderson C, Heneghan NR. Diagnostic accuracy of
392 upper limb neurodynamic tests for the assessment of peripheral neuropathic pain:
393 A systematic review. *Musculoskelet Sci Pract.* 2019;40:21-33.
394 doi:10.1016/j.msksp.2019.01.001
- 395 16. Bueno-Gracia E, Tricás-Moreno JM, Fanlo-Mazas P, et al. Validity of the Upper
396 Limb Neurodynamic Test 1 for the diagnosis of Carpal Tunnel Syndrome. The
397 role of structural differentiation. *Man Ther.* 2015;22:190-195.
398 doi:10.1016/j.math.2015.12.007
- 399 17. Ballesteros-Pérez R, Plaza-Manzano G, Urraca-Gesto A, et al. Effectiveness of
400 Nerve Gliding Exercises on Carpal Tunnel Syndrome: A Systematic Review. *J*
401 *Manipulative Physiol Ther.* 2017;40(1):50-59. doi:10.1016/j.jmpt.2016.10.004
- 402 18. Fernandez-de-Las Penas C, Ortega-Santiago R, de la Llave-Rincon AI, et al.
403 Manual Physical Therapy Versus Surgery for Carpal Tunnel Syndrome: A
404 Randomized Parallel-Group Trial. *J Pain.* 2015;16(11):1087-1094.
405 doi:10.1016/j.jpain.2015.07.012
- 406 19. Jiménez-Del-Barrio S, Estébanez-de-Miguel E, Bueno-Gracia E, Haddad-Garay
407 M, Tricás-Moreno JM, Hidalgo-García C. Effects of diacutaneous fibrolysis in
408 patients with mild to moderate symptomatic carpal tunnel syndrome: a
409 randomized controlled trial. *Clin Rehabil.* 2018;32(12):1645-1655.
410 doi:10.1177/0269215518787316
- 411 20. **Barra ME, Lopez C, Fernandez G, Murillo E, Villar E, Raya L. The**
412 **immediate effects of diacutaneous fibrolysis on pain and mobility in patients**
413 **suffering from painful shoulder: a randomized placebo-controlled pilot**
414 **study. Clin Rehabil.** 2011;25(4):339-348. doi:10.1177/0269215510385480;
415 **10.1177/0269215510385480**

21. Barra-Lopez ME, Lopez-de-Celis C, Fernandez Jentsch G, Raya-de-Cardenas L, Lucha-Lopez MO, Tricas-Moreno JM. Effectiveness of Diacutaneous Fibrolysis for the treatment of subacromial impingement syndrome: a randomised controlled trial. *Man Ther.* 2013;18(5):418-424. doi:10.1016/j.math.2013.02.006; 10.1016/j.math.2013.02.006
22. López-de-Celis C, Barra-López M-E, González-Rueda V, Bueno-Gracia E, Rodríguez-Rubio P-R, Tricás-Moreno J-M. Effectiveness of diacutaneous fibrolysis for the treatment of chronic lateral epicondylalgia: a randomized clinical trial. *Clin Rehabil.* 2018;32(5):644-653. doi:10.1177/0269215517738114
23. Veszely M, Guissard N, Duchateau J. Contribution à l'étude des effets de la fibrolyse diacutanée sur le triceps sural. *Ann Kinésithér.* 2000;2(t.27):54-59.
24. Lévéné M, Timmermans B, Duchateau J. Effet du crochetage myo-aponévrotique du triceps sural sur la tension passive et l'architecture musculaire à l'étirement. *Thérapie Man Chev pied.* 2009;9(92-93):56-61. doi:http://dx.doi.org/10.1016/S1779-0123(09)74708-4
25. Cobos-Carbó A, Augustovski F. Declaración CONSORT 2010: actualización de la lista de comprobación para informar ensayos clínicos aleatorizados de grupos paralelos. *Med Clin (Barc).* 2011. doi:10.1016/j.medcli.2010.09.034
26. Jablecki CK, Andary MT, Floeter MK, et al. Practice parameter: Electrodiagnostic studies in carpal tunnel syndrome. Report of the American Association of Electrodiagnostic Medicine, American Academy of Neurology, and the American Academy of Physical Medicine and Rehabilitation. *Neurology.* 2002;58(11):1589-1592. doi:10.1212/WNL.58.11.1589
27. Oteo A, Marín MT, Matas JA, Vaquero J. Spanish validation of the Boston

- 441 Carpal Tunnel Questionnaire. *Med Clin (Barc)*. 2016;146(6):247-253.
- 442 doi:10.1016/J.MEDCLE.2016.05.001
- 443 28. Leite JC, Jerosch-Herold C, Song F. A systematic review of the psychometric
- 444 properties of the Boston Carpal Tunnel Questionnaire. *BMC Musculoskelet*
- 445 *Disord*. 2006;7:78. doi:1471-2474-7-78
- 446 29. **Butler DS. *The Sensitive Nervous System*. 1st Editio. Adelaide, Australia:**
- 447 **Noigroup Publications; 2000;151-163**
- 448 30. Elvey R. Physical evaluation of the peripheral nervous system in disorders of
- 449 pain and dysfunction. *J Hand Ther*. 1997;10(2):122-129. doi:10.1016/S0894-
- 450 1130(97)80066-X
- 451 31. Selvaratnam P, Matyas TA, Glasgow EF. Noninvasive discrimination of brachial
- 452 plexus involvement in upper limb pain. *Spine (Phila Pa 1976)*. 1994;19(1):26-33.
- 453 doi:10.1097/00007632-199401000-00006
- 454 32. **Shacklock M. *Clinical Neurodynamics*. 1st Editio. Oxford: Elsevier; 2005;10-**
- 455 **121**
- 456 33. Boyd BS. Common interlimb asymmetries and neurogenic responses during
- 457 upper limb neurodynamic testing: implications for test interpretation. *J Hand*
- 458 *Ther*. 2011;25(1):56-63; quiz 64. doi:10.1016/j.jht.2011.09.004
- 459 34. Van der Heide B, Allison GT, Zusman M. Pain and muscular responses to a
- 460 neural tissue provocation test in the upper limb. *Man Ther*. 2001;6(3):154-162.
- 461 doi:10.1054/math.2001.0406
- 462 35. Boyd BS, Wanek L, Gray AT, Topp KS. Mechanosensitivity of the lower
- 463 extremity nervous system during straight-leg raise neurodynamic testing in
- 464 healthy individuals. *J Orthop Sports Phys Ther*. 2009;39(11):780-790.
- 465 doi:10.2519/jospt.2009.3002

36. Coppieters M, Stappaerts K, Wouters LL, Koen J. The Immediate Effects of a Cervical Lateral Glide Treatment Technique in Patients With Neurogenic Cervicobrachial Pain. *J Orthop Sport Phys Ther.* 2003;26(7):182-186. doi:10.1007/s00167-006-0045-6
37. Oliver GS, Rushton A. A study to explore the reliability and precision of intra and inter-rater measures of ULNT1 on an asymptomatic population. *Man Ther.* 2011;16(2):203-206. doi:10.1016/j.math.2010.05.009
38. Martínez MDA, Cubas CL, Gírbés EL. Ulnar nerve neurodynamic test: study of the normal sensory response in asymptomatic individuals. *J Ortho Sport Phys Ther.* 2014;44(6):450-456. doi:10.2519/jospt.2014.5207
39. Bland JD. A neurophysiological grading scale for carpal tunnel syndrome. *Muscle Nerve.* 2000;23(8):1280-1283. doi:10.1002/1097-4598(200008)23:8<1280::AID-MUS20>3.0.CO;2-Y
40. Cohen J. *Statistical Power Analysis for the Behavioral Sciences.* 2nd ed. Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1988.
41. Nee RJ, Jull G, Vicenzino B, Coppieters MW. The Validity of Upper Limb Neurodynamic Tests for Detecting Peripheral Neuropathic Pain. *J Orthop Sports Phys Ther.* 2012;42(5):413-424. doi:10.2519/jospt.2012.3988
42. Vanti C, Bonfiglioli R, Calabrese M, et al. Upper Limb Neurodynamic Test 1 and symptoms reproduction in carpal tunnel syndrome. A validity study. *Man Ther.* 2011;16(3):258-263. doi:10.1016/j.math.2010.11.003
43. Vanti C, Conteddu L, Guccione A, et al. The Upper Limb Neurodynamic Test 1: intra- and intertester reliability and the effect of several repetitions on pain and resistance. *J Manipulative Physiol Ther.* 2010;33(4):292-299. doi:10.1016/j.jmpt.2010.03.003

- 491 44. Chang YW, Hsieh SF, Horng YS, Chen HL, Lee KC, Horng YS. Comparative
492 effectiveness of ultrasound and paraffin therapy in patients with carpal tunnel
493 syndrome: a randomized trial. *BMC Musculoskelet Disord.* 2014;15:399.
494 doi:10.1186/1471-2474-15-399
- 495 45. Yagci I, Elmas O, Akcan E, Ustun I, Gunduz OH, Guven Z. Comparison of
496 splinting and splinting plus low-level laser therapy in idiopathic carpal tunnel
497 syndrome. *Clin Rheumatol.* 2009;28(9):1059-1065. doi:10.1007/s10067-009-
498 1213-0
- 499 46. Soyupek F, Yesildag A, Kutluhan S, et al. Determining the effectiveness of
500 various treatment modalities in carpal tunnel syndrome by ultrasonography and
501 comparing ultrasonographic findings with other outcomes. *Rheumatol Int.*
502 2012;32(10):3229-3234. doi:10.1007/s00296-011-2173-7
- 503 47. Frasca G, Maggi L, Padua L, et al. Short-term effects of local microwave
504 hyperthermia on pain and function in patients with mild to moderate carpal
505 tunnel syndrome: a double blind randomized sham-controlled trial. *Clin Rehabil.*
506 2011;25(12):1109-1118. doi:10.1177/0269215511400767
- 507 48. Page MJ, Massy-Westropp N, O'Connor D, Pitt V. Splinting for carpal tunnel
508 syndrome. *Cochrane database Syst Rev.* 2012;7:CD010003.
509 doi:10.1002/14651858.CD010003
- 510 49. Elliott R, Burkett B. Massage therapy as an effective treatment for carpal tunnel
511 syndrome. *J Bodyw Mov Ther.* 2013;17(3):332-338.
512 doi:10.1016/j.jbmt.2012.12.003; 10.1016/j.jbmt.2012.12.003
- 513 50. Fernández-de-las-Peñas C, Cleland J, Palacios-Ceña M, Fuensalida-Novo S,
514 Pareja JA, Alonso-Blanco C. The Effectiveness of Manual Therapy Versus
515 Surgery on Self-reported Function, Cervical Range of Motion, and Pinch Grip

- 516 Force in Carpal Tunnel Syndrome: A Randomized Clinical Trial. *J Orthop Sport*
 517 *Phys Ther.* 2017;47(3):151-161. doi:10.2519/jospt.2017.7090
- 518 51. Lohkamp M, Small K. Normal response to Upper Limb Neurodynamic Test 1
 519 and 2A. *Man Ther.* 2011;16(2):125-130. doi:10.1016/j.math.2010.07.008
- 520 52. Boyd BS. Common interlimb asymmetries and neurogenic responses during
 521 upper limb neurodynamic testing: implications for test interpretation. *J Hand*
 522 *Ther.* 2012;25(1):56-63; quiz 64. doi:10.1016/j.jht.2011.09.004
- 523 53. Lai WH, Shih YF, Lin PL, Chen WY, Ma HL. Normal neurodynamic responses
 524 of the femoral slump test. *Man Ther.* 2012;17(2):126-132.
 525 doi:10.1016/j.math.2011.10.003
- 526 54. Walsh J, Flatley M, Johnston N, Bennett K. Slump test: sensory responses in
 527 asymptomatic subjects. *J Man Manip Ther.* 2007;15(4):231-238.
 528 doi:10.1179/106698107790819413
- 529 55. **Flanagan M. The normal response to the ulnar nerve bias upper limb**
 530 **tension test. "Dissertation". Univ South Aust. 1993:151.**
- 531 56. Talebi GA, Saadat P, Javadian Y, Taghipour M. Manual therapy in the treatment
 532 of carpal tunnel syndrome in diabetic patients: A randomized clinical trial. *Casp*
 533 *J Intern Med.* 2018;9(3):283-289. doi:10.22088/cjim.9.3.283
- 534 57. Oskouei AE, Talebi GA, Shakouri SK, Ghabili K. Effects of neuromobilization
 535 maneuver on clinical and electrophysiological measures of patients with carpal
 536 tunnel syndrome. *J Phys Ther Sci.* 2014;26(7):1017-1022.
 537 doi:10.1589/jpts.26.1017
- 538 58. Maddali Bongi S, Signorini M, Bassetti M, Del Rosso A, Orlandi M, De
 539 Scisciolo G. A manual therapy intervention improves symptoms in patients with
 540 carpal tunnel syndrome: a pilot study. *Rheumatol Int.* 2013;33(5):1233-1241.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

doi:10.1007/s00296-012-2507-0

59. Coppieters M, Stappaerts K, Everaert D, Staes F. Addition of Test Components During Neurodynamic Testing: Effect on Range of Motion and Sensory Responses. *J Orthop Sport Phys Ther.* 2001;31(5):226-237. doi:10.2519/jospt.2001.31.5.226

60. Dilley A, Lynn B, Pang SJ. Pressure and stretch mechanosensitivity of peripheral nerve fibres following local inflammation of the nerve trunk. *Pain.* 2005;117(3):462-472. doi:10.1016/j.pain.2005.08.018

61. Cleland J a, Childs JD, Palmer J a, Eberhart S. Slump stretching in the management of non-radicular low back pain: a pilot clinical trial. *Man Ther.* 2006;11(4):279-286. doi:10.1016/j.math.2005.07.002

62. Coppieters M, Alshami AM, Hodges PW. An experimental pain model to investigate the specificity of the neurodynamic test for the median nerve in the differential diagnosis of hand symptoms. *Arch Phys Med Rehabil.* 2006;87(10):1412-1417. doi:10.1016/j.apmr.2006.06.012

Figure 1. ULNT1 sequence and structural differentiation maneuver.



90° Shoulder Abduction



90° Shoulder external rotation



Forearm supination



Wrist and fingers extension



Elbow extension



Structural Differentiation Maneuver

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Independent variable application



A. Application of Diacutaneous Fibrolysis



B. Application of Sham Technique


Figure 3. Flowchart of patient recruitment.

Figure 4. Symptoms' location (stretching, pain or tightness) in ULNT1. Body chart. Pre: Baseline; POST; end of treatment.




TABLE 1. Descriptive baseline characteristics of study sample ^a.

Demographics ^b	DF group (n=26)	Sham group (n=26)	Significance
Gender (male/female)	5/21	4/22	p= 0.10 ^c
Age (years) Mean (SD)	45.5 (9.6)	49.6 (7.6)	U = 253.5; p = 0.12 ^d
BMI (kg/cm ²) Mean (SD)	24.9 (2.8)	25.6 (2.9)	t= -0.85; p = 0.40 ^e
Symptoms duration (months) Mean (SD)	25.8 (23.9)	27.6 (39.2)	U = 322.0; p = 0.77 ^d

^a BMI = body mass index, DF = diacutaneous fibrolysis^bContinuous variables are reported as mean (SD) and categorical variables are reported as n.^c Chi-square test, ^dU-Mann Whitney test, ^eStudent-t test.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

TABLE 2. Baseline, final values, differences and effect sizes for the elbow extension ROM, the intensity of the response during ULNT1 and sensory conduction velocity of median nerve in wrist^a.

Outcome group ^b	Baseline	End of treatment	Within group changes (95%CI)	Within group effect sizes	Between-group differences in change scores (95%CI)	Between-group effect sizes
ULNT1 elbow extensión (°)						
Sham group (n=26)	97.3 (10.1)	96.8 (7.8)	-0.4 (-5.2, 4.2)	0.0	28.46 (19.2, 37.7)	1.7
DF group (n=26)	97.8 (7.4)	125.3 (22.1)	27.4 (19.6, 35.2)	-1.6		
ULNT1 VAS (0-10)						
Sham group (n=26)	4.8 (2.0)	4.2 (2.0)	-0.5 (-1.2, 0.0)	0.3	-2.0 (-2.9, -1.0)	-1.2
DF group (n=26)	3.8 (1.7)	2.2 (1.2)	-1.6 (-2.2, -1.0)	1.0		
SCV median nerve (m/s)						
Sham group (n=26)	41.2 (5.5)	40.8 (5.8)	-0.3 (-1.8, 1.1)	0.0	5.8 (2.5, 9.2)	0.9
DF group (n=26)	42.7 (5.9)	46.7 (6.0)	3.9 (1.8, 6.0)	-0.6		
BCTQ						
Sham group (n=26)	2.4 (0.7)	2.3 (0.8)	0.1 (-0.5,0.3)	0.1	1.0 (1.4,0.7)	1.5
DF group (n= 26)	2.4 (0.4)	1.3 (0.4)	1.2 (0.9,1.5)	2.75		

^a DF: diacutaneous fibrolysis; ULNT1: Upper Limb Neurodynamic Test 1; SCV: sensory conduction velocity; BCTQ: Boston Carpal Tunnel Questionnaire

^bValues are expressed as mean ± SD for baseline and final means and as mean (95% confidence interval) for within-group and between-group change scores.

653

654 **TABLE 3.** Baseline, final, differences between groups and effect sizes between groups of the type of sensation provoked in ULNT1^a.

655

ULNT1 ^b		Stretching	Pain	Tingling	Pricking	Numbness	Burning
Baseline	Sham group (n=26)	17 (65.4)	6 (23.1)	0	0	3 (11.5)	0
	DF group (n=26)	19 (73.1)	5 (19.2)	0	0	2 (7.7)	0
Final	Sham group (n=26)	13 (50.0)	10 (38.5)	0	0	3(11.5)	0
	DF group (n=26)	21 (80.8)	4 (15.4)	0	0	1 (3.8)	0

656

657 ^aULNT1: ULNT1: Upper Limb Neurodynamic Test 1; DF: diacutaneous fibrolysis658 ^bValues are frequency (%).

659

660

661

662

Effects of diacutaneous fibrolysis in patients with mild to moderate symptomatic carpal tunnel syndrome: a randomized controlled trial

Sandra Jiménez del Barrio¹, Elena Estébanez de Miguel^{2,3},
Elena Bueno Gracia^{2,3}, María Haddad Garay³,
José Miguel Tricás Moreno^{2,3} and César Hidalgo García^{2,3}

Abstract

Objective: To compare the effects of diacutaneous fibrolysis with sham in patients with mild to moderate carpal tunnel syndrome.

Design: Double-blind (patient and evaluator) randomized controlled trial.

Setting: Miguel Servet University Hospital, Zaragoza, Spain.

Subjects: A total of 52 patients (72 wrists) with carpal tunnel syndrome, 41 women and 11 men, mean age was 46.9 (8.8) years. They were divided into two groups: diacutaneous fibrolysis group and sham group.

Interventions: Real diacutaneous fibrolysis in diacutaneous fibrolysis group and sham diacutaneous fibrolysis in sham group. Both groups received five sessions in the forearm, wrist and hand.

Main measures: Neurophysiological parameters assessed at baseline and at the end of the treatment. Intensity of nocturnal symptoms (visual analogue scale (VAS)) and upper limb functional capacity (Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire) at baseline, at the end of the treatment and one month after treatment.

Results: Diacutaneous fibrolysis group (n = 30 wrists) improved in nerve conduction distal motor latency (mean difference: -0.26, 95% confidence interval (CI): -0.49/-0.26), sensory conduction velocity (mean difference: 6.52, 95% CI: 3.52/9.51), intensity of nocturnal symptoms (mean difference: -2.24, 95% CI: -4.08/-2.04) and upper limb functional capacity (mean difference: -19, 95% CI: -26.1/-11.9) compared to the sham group (n = 30 wrists) (P < 0.02, P < 0.01, P < 0.01 and P < 0.01, respectively). At one-month follow-up, improvements in the nocturnal symptoms and upper limb functional capacity were maintained compared to the sham group (P < 0.01).

Conclusion: Diacutaneous fibrolysis provides short-term and one-month follow-up, improvements in sensory conduction velocity, motor distal latency, symptoms and functional capacity in patients with mild to moderate carpal tunnel syndrome.

¹University of Valladolid, Valladolid, Spain

²University of Zaragoza, Zaragoza, Spain

³Universitary Clinical Hospital Miguel Servet, Zaragoza, Spain

Corresponding author:

Sandra Jiménez del Barrio, University of Valladolid, Valladolid
47002, Spain.

Email: sandra.jimenez.barrio@uva.es

Clinical Rehabilitation
1-11

© The Author(s) 2018

Reprints and permissions:

sagepub.co.uk/journalsPermissions.nav

DOI: 10.1177/0269215518787316

journals.sagepub.com/home/cre



Keywords

Carpal tunnel syndrome, physical therapy modalities, pain and randomized controlled trial

Received: 19 July 2017; accepted: 16 June 2018

Introduction

Non-surgical treatment is generally prescribed as the first-line approach to patients with mild to moderate carpal tunnel syndrome.¹ Current treatments in the mild and moderate stages in carpal tunnel syndrome involve the use of orthotics such as splints or orally administered drugs.^{2–4} However, the negative consequences arising from their continued use must be taken into account.^{5–8} Other conservative techniques have also been proposed, such as electrotherapy,^{1,9} mobilization of the carpal bones, ultrasound and even combinations of techniques, but their effectiveness cannot be confirmed because of the lack of studies with an adequate methodological quality.^{9–17} Recent studies propose techniques with approaches that integrate the treatment of structures taking the continuity of the nerve into account, not only at a local level.^{18,19} These results, coupled with the clear involvement of adjacent tissues in the path of the nerve, justify an approach dealing with the soft tissue in the adjacent regions and not only locally in carpal tunnel structures in the wrist.

In addition to compressive signs on the median nerve at the carpal tunnel, biomechanical changes of the transverse carpal ligament and degenerative changes to the connective tissue and tenosynovium have been shown in carpal tunnel syndrome patients.^{20–22}

Diacutaneous fibrolysis is a physiotherapeutic technique developed from Cyriax deep friction massage principles, but a set of metallic hooks are used to achieve a deeper and more precise application than manual. Diacutaneous fibrolysis has been proven to be effective improving symptoms and function in other musculoskeletal disorders such as shoulder pain,^{23,24} lateral epicondylalgia and triceps surae tendon muscle reflexes.^{25,26} To our knowledge, they are no studies on diacutaneous fibrolysis technique effectiveness in carpal tunnel syndrome.

Our hypothesis is that this technique could be effective for improving alterations in the connective tissues adjacent to the nerve and could improve the function and symptoms in mild to moderate carpal tunnel syndrome patients.

The aim of this study was to evaluate the effect of five sessions of diacutaneous fibrolysis on the myofascial tissues of the forearm, wrist and hand in carpal tunnel syndrome patients with mild and moderate involvement of the upper limb in terms of nerve conduction, symptoms and functional capacity.

Methods

Design

A double-blind (patient and evaluator) randomized controlled trial was carried out between April to September 2016. The study was registered in ClinicalTrials.gov (C.I.P114/00086) and was approved by the Clinical Research Ethics Committee of Aragón with registration number (CP13/2014).

Recruitment procedures

Subjects with mild to moderate carpal tunnel syndrome diagnosed by neurophysiological test were recruited from the neurophysiology service of the Miguel Servet Hospital (Zaragoza, Spain). The sample size was calculated for all dependent variables, estimating a two-tail test, a level of significance of 0.05, a power of 0.8 and a follow-up loss rate of 15%. The highest value (36 affected wrists per group) was obtained with data of the sensory conduction velocity (expected size 4 and SD: 5.3) previously reported in a pilot study. As there were two groups in this study (diacutaneous fibrolysis group and sham group), the total sample size was

Table 1. Inclusion and exclusion criteria.

Inclusion criteria	Exclusion criteria
Having been medically diagnosed with CTS after electrophysiological tests and presenting mild to moderate involvement. This test was performed according to the standards established by the “American Academy of Physical Medicine and Rehabilitation”	Previous surgery in the carpal tunnel in the same limb
Being between 18 and 65 years old	Other pathologies that may be associated with CTS: traumas, pathologies or disorders of the upper limb or cervical spine (cervical radiculopathy, cervical sprain, etc.) or prior cervical surgery
Having sufficient understanding and capacity to communicate their symptoms and to complete the questionnaires	Concurrent comorbidities that may be the cause and interfere with the treatment of the CTS: diabetes mellitus, hypothyroidism, rheumatoid arthritis, fibromyalgia, reflex sympathetic dysfunction, obesity, renal disease, alcoholism, significant vitamin deficiency and associated viral or bacterial processes
The ability to maintain a supine position without triggering symptoms or altering the patient’s condition	Pregnancy
Voluntarily accepting and consenting to participate in the study	Oral drugs, physiotherapy treatment or infiltrations in the upper limb in the last three months
	Presenting red flags, such as processes of malignancy, inflammation, fever etc. or psychological contraindications that could interfere with the normal progress of the study
	Specific contraindications for the diacutaneous fibrolysis treatment, such as skin disorders (such as diaphanous and hypotrophy (or) ulcerous skin (or) dermatosis), a poor trophic state of the circulatory system or an overdeveloped network of surface veins or the consumption of antiplatelet agents

CTS: carpal tunnel syndrome.

72 affected wrists. The inclusion and exclusion criteria are listed in Table 1. All participants were randomly classified either into the diacutaneous fibrolysis group or the sham group. For the randomization process, an external evaluator randomized the intervention to each participant using the research randomizer (version 4.0) computer software. Both evaluators and patients were blind to the group assignment. In bilateral affectations, the same intervention was performed in both sides, in order to maintain blinding.

Data collection

The sensory conduction velocity and the motor distal latency of the median nerve at the wrist was measured by neurophysiological assessment^{27,28} at the beginning and after five sessions of treatment. Neurophysiological tests were measured by a neurophysiologist. The intensity of nocturnal symptoms was also measured using a visual analogue scale (VAS) of 100-mm length, where 0 was “no pain” and 100 was “maximum pain” with no

intermediate marks,²⁹ at baseline, at the end of the treatment and after one-month follow-up. The functional capacity of the upper limb was also evaluated with the Disabilities of the Arm, Shoulder and Hand questionnaire (DASH)^{30,31} at baseline (T0), at the end of treatment (T1) and at one-month follow-up (T2). All these functional measures were performed by two physiotherapists. To determine the degree of masking, each patient was asked which technique (sham or real diacutaneous fibrolysis) they thought that they had received.

Interventions

All patients participated in five sessions of real or sham treatment 20 minutes each. All intervention lasted an average of 17.77 days (SD: 0.8) with an interval of two to five days between each session, according to a person’s availability. The diacutaneous fibrolysis group received the real technique. The technique was applied using the hook on the intermuscular septa of the ventral musculature of the forearm: the pronator teres, the flexor carpi

radialis, the palmaris longus, the flexor carpi ulnaris and the finger flexors, from the proximal to the distal region, toward the wrist and ending at the approach to the flexor tendons and palmar fascia. The hook was applied with necessary pressure for covering the structure to be moved, and a short and fast traction in transverse direction made with the hook remains fixed in the skin and the underlying soft tissues^{23,24} (Figure 2).

The sham group received simulated technique. The hook was applied in the same regions and in the same direction, but at a superficial level without generating mechanical traction on the deep fibers of the soft tissue²³ (Figure 2).

Both real and sham techniques were provided by the same physical therapist, who was the only person aware of patients allocation.

Data analysis

SPSS version 20.0 software for MAC was used for the statistical analysis.

A descriptive analysis was performed on the first measurement of all the variables considered. The assumption of normality was assessed using the Shapiro–Wilk test. In the between group comparisons, the chi-square test was used for qualitative variables. For quantitative variables, Student's t-test was performed if the criteria for its applicability were met; otherwise, the Mann–Whitney U test was used. The differences between groups were calculated. The level of significance was set at $\alpha=0.05$.

Results

The study flowchart is reported in Figure 1. A total of 52 patients (72 wrists) affected by mild to moderate carpal tunnel syndrome consent to participate in the trial and were randomly allocated to either the diacutaneous fibrolysis group ($n=25$, 36 wrists) or the sham group ($n=27$, 36 wrists). Of the 52 patients, 41 were female (78.85%) and 11 were male (21.15%) with a mean age of 46.9 years (SD: 8.8). Eight subjects dropped out of the study during treatment sessions. No adverse events or side-effects were reported nor observed for any

participant. At baseline, the two groups showed similar demographic characteristics. The baseline demographic and clinical characteristics of the enrolled participants are shown in Table 2.

Statistically significant differences were observed after treatment (T1) in the intensity of nocturnal symptoms in the diacutaneous fibrolysis group with a significant reduction compared to the sham group ($P<0.01$; Table 3). There was a statistically significant improvement in functional capacity with the upper limb in the diacutaneous fibrolysis group compared to the sham group ($P<0.01$; Table 3). This improvement also persisted significantly at one-month follow-up (T2), as shown in Table 3.

After treatment (T1), the diacutaneous fibrolysis group achieved a statistically significant improvement in sensory nerve conduction velocity ($P<0.01$) and in motor conduction latency ($P<0.01$), in comparison to the sham group, as shown in Table 3.

No statistically significant difference ($P=0.57$) for the degree of masking (Table 4).

Discussion

In this study, five diacutaneous fibrolysis sessions produced short-term improvements in nocturnal symptoms, functional capacity with upper limb and neurophysiological parameters compared with sham diacutaneous fibrolysis, and those improvements persisted after one-month follow-up.

The comparison with our study is difficult for several reasons: the sample characteristics, the severity of the pathology and the treatment applied.^{32,33} However, this finding is highly relevant if we consider the possible adverse effects and iatrogenic lesions that may occur, such as infections, damage to the adjacent tendons and nerves or inflammation.^{7,8} This shows that an analgesic effect can be achieved without taking oral drugs, thereby avoiding their negative consequences. Other conservative techniques with a solely local treatment also fail to achieve better results for pain.^{34–36} Furthermore, our results are similar to those obtained in other studies that used a more global approach.^{19,37} These previous researches even obtained superior results, although




Figure 1. Flowchart of patient recruitment. FD: diacutaneous fibrolysis; CTS: carpal tunnel syndrome.

it must be emphasized that these studies included patients with severe involvement and with more intense symptoms at baseline. It should be noted that these studies adopted a broader approach,^{19,37}

including regions such as the cervical spine and the shoulder girdle. Importantly, in our study, the approach began with the insertion of the palmar flexors muscles of the carpus, and no techniques




Figure 2. (a) Application of real diacutaneous fibrolysis, (b) application of sham diacutaneous fibrolysis.

were performed for more proximal regions because proximal compressive syndromes such as radiculopathy and thoracic outlet syndrome were excluded. However, a broader approach may not be justified if the possible coexistence of other associated compressive syndromes has not been evaluated beforehand.

Functional capacity in the upper limb improves after diacutaneous fibrolysis technique and after one-month follow-up and it achieved the minimal clinically relevant difference for this questionnaire.³⁸⁻⁴⁰ The improvements achieved were superior to those in studies in which a conservative treatment was performed, in combination with various treatment techniques that focused on more local splint and paraffin structures,⁴¹ and they were also superior to those obtained with neural gliding techniques.^{42,43}

The improvements not only were in clinical variables but also in neurophysiological parameters values. It is a very important factor because

electroneurogram is the gold standard test and is considered an appropriate measure to assess the state of the median nerve in patients with carpal tunnel syndrome after surgery.⁴⁴ Although we found no previous studies that provide data on the minimum detectable difference in the values obtained in the neurophysiological parameters, we obtained statistically significant improvements in our study. Previous studies have determined positive effects in neurophysiological parameters with some oral steroids⁴⁵ or other local treatments such as infiltrations.³² However, it is necessary to consider the adverse effects resulting from continuous application of these treatments.^{7,8} Other studies only focusing on treatment with local structures, such as splints, electrotherapy or the combination of several techniques failed to lead to improvements in the neurophysiological parameters.^{9,41,46} Improvements have been achieved in nerve conduction only in some cases,

Table 2. Patients' baseline characteristics.

Variables	Diacutaneous fibrolysis group, n = 25 (36 wrists)	Sham group, n = 27 (36 wrists)	P value
Age in years (mean and SD)	44.97 (9.34)	48.83 (7.98)	0.08 ^a
Sex			0.77 ^b
Male	6 (20)	5 (16.7)	
Female	19 (80)	22 (83.3)	
BMI (Kg/m ²) (mean and SD)	24.78 (2.65)	25.32 (2.97)	0.57 ^a
Wrist circumference (cm) (mean and SD)	15.94 (1.18)	15.77 (1.14)	0.36 ^a
Work activity (outside home), n (%)	21 (84)	25 (92.59)	0.34 ^b
Active	4 (16)	2 (7.41)	
Not working			
Use of the wrist in sports (n and %)			0.5 ^b
Yes	7 (28)	6 (22.2)	
No	18 (72)	21 (78.8)	
Duration of symptoms in months (mean and SD)	25.68 (28.35)	25.06 (20.8)	0.49 ^c
Affected wrist (n and %)			0.072 ^b
Right	19 (52.7)	26 (72.2)	
Left	17 (47.3)	10 (27.8)	

BMI: body mass index.

^aMann-Whitney U test.

^bChi-square test.

^cStudent's t-test.

involving a combination of several treatment techniques and with more sessions than in our study.^{36,41,46}

The techniques that treated adjacent soft tissues include manual therapy techniques, consisting of mobilization of the soft tissue and the fascia, similar to our study.^{19,47} The possible explanation for the better results obtained using this kind of approach are the relationships between the different musculo-skeletal structures, which have been demonstrated for between the palmar fascia, transverse ligament, flexor retinaculum and antebrachial fascia.^{22,48} As has been demonstrated, there is not only an alteration in the nerve tissues, but also in the adjacent soft tissues.^{22,49,50}

However, in our study, we obtained improvements superior to other studies in which these adjacent tissues were treated. This may suggest that despite the similarities in the type of approach used in this study and ours, diacutaneous fibrolysis may be crucial in obtaining the best results.

This study has some limitations, first the relatively small number of patients and strict inclusion

criteria in the sample included, that the data cannot be extrapolated to all patients with carpal tunnel syndrome. Also, our sample comprised mild to moderate affection with carpal tunnel syndrome, so the findings cannot be generalized to patients with severe carpal tunnel syndrome. Second, the relatively slight loss of patients and the lack of long-term follow-up. Third, it has not been compared with other conservative treatments previously used. Finally, although all the participants were asked to maintain any pharmaceutical treatments, there were using for carpal tunnel syndrome during the duration of the study, we did not specifically monitor.

Given the results of this study, we believe that diacutaneous fibrolysis will improve the prognosis of patients in the mild and moderate phases of carpal tunnel syndrome. This has a very important clinical implication, since if this approach is undertaken at an early stage, it could avoid progression of the syndrome and thereby prevent the need for surgery, which as mentioned above, has major complications and risks.

Table 3. Outcome variable values by group: at baseline, at the end of treatment and at short-term follow-up.

Variable	T0				T1 (17.77 days, SD:0.8)				T2			
	Sham group		Diacutaneous fibrolysis vs sham		Diacutaneous fibrolysis group, 17.93 days (SD: 0.89)		Sham group, 17.6 days (SD: 0.67)		Diacutaneous fibrolysis group		Sham group	
	Mean (SD), (n = 25) 36 wrists	Mean (SD), (n = 27) 36 wrists	P value		Mean (SD), (n = 20) 30 wrists	Mean (SD), (n = 24) 30 wrists	Mean (SD), (n = 24) 30 wrists		Mean (SD), (n = 20) 30 wrists	Mean (SD), (n = 24) 30 wrists	Mean (SD), (n = 24) 30 wrists	P value
VAS nocturnal pain (0–10)	3.32 (2.1)	3.6 (2.29)	0.53		0.42 (0.82)	3.48 (2.67)	–2.24 (–4.08/–2.04)	<0.01 ^a	0.93 (1.78)	3.99 (2.42)	–3.05 (–4.07/–2.03)	<0.01 ^a
DASH Questionnaire (0–100)	17.62 (8.89)	22.79 (13.49)	0.1		4.64 (5.6)	20.47 (15.16)	–19.00 (–26.1/–11.9)	<0.01 ^b	5.17 (8.01)	23.11 (14.8)	–21.53 (–28.6/–14.4)	<0.01 ^b
DML (m/s)	3.92 (0.52)	3.97 (0.33)	0.23		3.74 (0.49)	3.99 (0.39)	–0.26 (–0.49/–0.26)	0.029 ^b				
SCV (m/s)	42.69 (5.2)	41.26 (4.81)	0.27		46.91 (5.78)	40.39 (5.82)	6.52 (3.52/9.51)	<0.01 ^b				

T0: pretreatment assessment; T1: posttreatment assessment; T2: one-month follow-up; VAS: visual analogue scale; DASH: Disabilities of the Arm, Shoulder and Hand; DML: distal motor latency;

SCV: sensory conduction velocity.

^aMann–Whitney U test.^bStudent's t-test.

Table 4. Measurement of blinding technique. Chi-square test.

	Blinding of the technique			P value
	Do not know/no answer	Diacutaneous fibrolysis	Sham	
Diacutaneous fibrolysis group (n = 20, 30 wrists)	10	14	6	0.572 ^a
Sham group (n = 24, 30 wrists)	14	11	5	

^aChi-square test.**Clinical messages**

- Diacutaneous fibrolysis provides short-term and one-month follow-up improvements in sensory conduction velocity and motor distal latency.
- The application of five sessions of diacutaneous fibrolysis in the region of the forearm, wrist and hand in patients with mild and moderate carpal tunnel syndrome improves symptomatology and functional capacity and is reflected in the improvement of nerve conduction.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship and/or publication of this article.

ORCID iD

Sandra Jiménez del Barrio  <https://orcid.org/0000-0002-7460-3061>

References

1. Frasca G, Maggi L, Padua L, et al. Short-term effects of local microwave hyperthermia on pain and function in patients with mild to moderate carpal tunnel syndrome: a double blind randomized sham-controlled trial. *Clin Rehabil* 2011; 25(12): 1109–1118.
2. Bringer TL, Rogers JC, Holm MB, et al. Efficacy of a fabricated customized splint and tendon and nerve gliding exercises for the treatment of carpal tunnel syndrome: a randomized controlled trial. *Arch Phys Med Rehabil* 2007; 88(11): 1429–1435.
3. Burke FD. Carpal tunnel syndrome: reconciling “demand management” with clinical need. *J Hand Surg Br* 2000; 25(2): 121–127.
4. Manente G, Torrieri F, Di Blasio F, et al. An innovative hand brace for carpal tunnel syndrome: a randomized controlled trial. *Muscle Nerve* 2001; 24(8): 1020–1025.
5. Harirforoosh S, Asghar W and Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. *J Pharm Pharm Sci* 2013; 16(5): 821–847.
6. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy Asthma Clin Immunol* 2013; 9(1): 30.
7. Kushner SH, Brien WW, Johnson D, et al. Complications associated with carpal tunnel release. *Orthop Rev* 1991; 20(4): 346–352.
8. Braun RM, Rechin M and Fowler E. Complications related to carpal tunnel release. *Hand Clin* 2002; 18(2): 347–357.
9. Ebenbichler GR, Resch KL, Nicolakis P, et al. Ultrasound treatment for treating the carpal tunnel syndrome: randomized “sham” controlled trial. *BMJ* 1998; 316(7133): 731–735.
10. Carlson H, Colbert A, Fryd J, et al. Current options for nonsurgical management of carpal tunnel syndrome. *Int J Clin Rheumatol* 2010; 5(1): 129–142.
11. Graham B. Nonsurgical treatment of carpal tunnel syndrome. *J Hand Surg Am* 2009; 34(3): 531–534.
12. Huisstede BM, Friden J, Coert JH, et al. Carpal tunnel syndrome: hand surgeons, hand therapists, and physical medicine and rehabilitation physicians agree on a multidisciplinary treatment guideline-results from the European HANDGUIDE Study. *Arch Phys Med Rehabil* 2014; 95(12): 2253–2263.
13. Kim SD. Efficacy of tendon and nerve gliding exercises for carpal tunnel syndrome: a systematic review of randomized controlled trials. *J Phys Ther Sci* 2015; 27(8): 2645–2648.
14. O'Connor D, Marshall S and Massy-Westropp N. Non-surgical treatment (other than steroid injection) for carpal

- tunnel syndrome. *Cochrane Database Syst Rev* 2003; 1: CD00321.
15. Page MJ, O'Connor D, Pitt V, et al. Therapeutic ultrasound for carpal tunnel syndrome. *Cochrane Database Syst Rev* 2013; 283: CD009601.
 16. Bakhtiari AH and Rashidy-Pour A. Ultrasound and laser therapy in the treatment of carpal tunnel syndrome. *Aust J Physiother* 2004; 50(3): 147–151.
 17. Oztas O, Turan B, Bora I, et al. Ultrasound therapy effect in carpal tunnel syndrome. *Arch Phys Med Rehabil* 1998; 79(12): 1540–1544.
 18. Burke J, Buchberger DJ, Carey-Loghmani MT, et al. A pilot study comparing two manual therapy interventions for carpal tunnel syndrome. *J Manipulative Physiol Ther* 2007; 30(1): 50–61.
 19. Fernández-de-las-Peñas C, Cleland J, Palacios-Ceña M, et al. The effectiveness of manual therapy versus surgery on self-reported function, cervical range of motion, and pinch grip force in carpal tunnel syndrome: a randomized clinical trial. *J Orthop Sports Phys Ther* 2017; 47(3): 151–161.
 20. Schuind F, Ventura M and Pasteels J. Idiopathic carpal tunnel syndrome: histologic study of flexor tendon synovium. *J Hand Surg Am* 1990; 15(3): 497–503.
 21. Allampallam K, Chakraborty J, Bose KK, et al. Explant culture, immunofluorescence and electron-microscopic study of flexor retinaculum in carpal tunnel syndrome. *J Occup Environ Med* 1996; 38(3): 264–271.
 22. Yesil M, Bacakaoglu AK and Dogan M. Are myofibroblasts activated in idiopathic carpal tunnel syndrome? An immunohistochemical study. *Ekleml Hastalik Cerrahisi* 2014; 25(3): 133–140.
 23. Barra ME, Lopez C, Fernandez G, et al. The immediate effects of diacutaneous fibrolysis on pain and mobility in patients suffering from painful shoulder: a randomized placebo-controlled pilot study. *Clin Rehabil* 2011; 25(4): 339–348.
 24. Barra López ME, López de Celis C, Fernández Jentsch G, et al. Effectiveness of diacutaneous fibrolysis for the treatment of subacromial impingement syndrome: a randomized controlled trial. *Man Ther* 2013; 18(5): 418–424.
 25. Veszely M, Guissard N and Duchateau J. Contribution à l'étude des effets de la fibrolyse diacutanée sur le triceps sural. *Ann Kinésithér* 2000; 2(27): 54–59.
 26. Lévénéz M, Timmermans B and Duchateau J. Effet du crochetaje myo-aponévrotique du triceps sural sur la tension passive et l'architecture musculaire à l'étirement. *Thérapie Man Chev Pied* 2009; 9(92–93): 56–61.
 27. Jablecki CK, Andary MT, Floeter MK, et al. Practice parameter: electrodiagnostic studies in carpal tunnel syndrome. Report of the American Association of Electrodiagnostic Medicine, American Academy of Neurology, and the American Academy of Physical Medicine and Rehabilitation. *Neurology* 2002; 58(11): 1589–1592.
 28. Bland JD. A neurophysiological grading scale for carpal tunnel syndrome. *Muscle Nerve* 2000; 23(8): 1280–1283.
 29. Jensen MP, Turner JA, Romano JM, et al. Comparative reliability and validity of chronic pain intensity measures. *Pain* 1999; 83(2): 157–162.
 30. Hervas MT, Navarro Collado MJ, Peiro S, et al. Spanish version of the DASH questionnaire. Cross-cultural adaptation, reliability, validity and responsiveness. *Med Clin* 2006; 127(12): 441–447.
 31. Jester A, Harth A, Wind G, et al. Disabilities of the arm, shoulder and hand (DASH) questionnaire: determining functional activity profiles in patients with upper extremity disorders. *J Hand Surg Br* 2005; 30(1): 23–28.
 32. Karadas O, Tok F, Akarsu S, et al. Triamcinolone acetate vs procaine hydrochloride injection in the management of carpal tunnel syndrome: randomized placebo-controlled study. *J Rehabil Med* 2012; 44(7): 601–604.
 33. Celiker R, Arslan S and Inanici F. Corticosteroid injection vs nonsteroidal antiinflammatory drug and splinting in carpal tunnel syndrome. *Am J Phys Med Rehabil* 2002; 81(3): 182–186.
 34. Yang CP, Hsieh CL, Wang NH, et al. Acupuncture in patients with carpal tunnel syndrome: a randomized controlled trial. *Clin J Pain* 2009; 25(4): 327–333.
 35. Joe-Air J, Wen-Dien C, Jih-Huah W, et al. Low-level laser treatment relieves pain and neurological symptoms in patients with carpal tunnel syndrome. *J Phys Ther Sci* 2011; 23(4): 661–665.
 36. Günay BALPA. The effectiveness of carpal bone mobilization accompanied by night splinting in idiopathic carpal tunnel syndrome. *Turkish J Phys Med Rehabil* 2015; 61(1): 45.
 37. Elliott R and Burkett B. Massage therapy as an effective treatment for carpal tunnel syndrome. *J Bodyw Mov Ther* 2013; 17(3): 332–338.
 38. Jain R, Hudak PL and Bowen CVA. Validity of health status measures in patients with ulnar wrist disorders. *J Hand Ther* 2001; 14(2): 147–153.
 39. Franchignoni F, Vercelli S, Giordano A, et al. Minimal clinically important difference of the disabilities of the arm, shoulder and hand outcome measure (DASH) and its shortened version (QuickDASH). *J Orthop Sports Phys Ther* 2014; 44(1): 30–39.
 40. Lundquist CB, Døssing K and Christiansen DH. Responsiveness of a Danish version of the disabilities of the arm, shoulder and hand (DASH) questionnaire. *Dan Med J* 2014; 61(4): A4813.
 41. Yagci I, Elmas O, Akcan E, et al. Comparison of splinting and splinting plus low-level laser therapy in idiopathic carpal tunnel syndrome. *Clin Rheumatol* 2009; 28(9): 1059–1065.
 42. Horng YS, Hsieh SF, Tu YK, et al. The comparative effectiveness of tendon and nerve gliding exercises in patients with carpal tunnel syndrome: a randomized trial. *Am J Phys Med Rehabil* 2011; 90(6): 435–442.
 43. Akalin E, El O, Peker O, et al. Treatment of carpal tunnel syndrome with nerve and tendon gliding exercises. *Am J Phys Med Rehabil* 2002; 81(2): 108–113.

44. Kanatani T, Fujioka H, Kurosaka M, et al. Delayed electrophysiological recovery after carpal tunnel release for advanced carpal tunnel syndrome: a two-year follow-up study. *J Clin Neurophysiol* 2013; 30(1): 95–97.
45. Chang MH, Ger LP, Hsieh PF, et al. A randomized clinical trial of oral steroids in the treatment of carpal tunnel syndrome: a long term follow up. *J Neurol Neurosurg Psychiatry* 2002; 73(6): 710–714.
46. Casale R, Damiani C, Maestri R, et al. Pain and electrophysiological parameters are improved by combined 830-1064 high-intensity LASER in symptomatic carpal tunnel syndrome versus transcutaneous electrical nerve stimulation. A randomized controlled study. *Eur J Phys Rehabil Med* 2013; 49(2): 205–211.
47. Maddali Bongi S, Signorini M, Bassetti M, et al. A manual therapy intervention improves symptoms in patients with carpal tunnel syndrome: a pilot study. *Rheumatol Int* 2013; 33(5): 1233–1241.
48. Guimberteau J-C. Le système multifibrillaire par son organization fractale et irrégulière introduit à des notions non lineaires. *Entrée matière vivante* 2012; 57(5): 515–516.
49. Engber DW. Myofibroblasts and the carpal tunnel syndrome. *Iowa Orthop J* 1984; 4: 57–59.
50. Yoshii Y, Zhao C, Zhao KD, et al. The effect of wrist position on the relative motion of tendon, nerve, and subsynovial connective tissue within the carpal tunnel in a human cadaver model. *J Orthop Res* 2008; 26(8): 1153–1158.